IJMM International Journal of Molecular Medicine 1107-3756 1791-244X D.A. Spandidos 10.3892/ijmm.2018.3999 ijmm-43-02-0709 Articles Astragaloside IV ameliorates high glucose-induced renal tubular epithelial-mesenchymal transition by blocking mTORC1/p70S6K signaling in HK-2 cells ChenXiao1* YangYang2* LiuChenxu3* ChenZhigao1 WangDongdong4 Department of Pharmacy, The People’s Hospital of Jiangyin, Jiangyin, Jiangsu 214400 Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu 221004 Department of Pharmacy, Shenzhen Hospital of Southern Medical University, Shenzhen, Guangdong 518000 Department of Pharmacy, Children’s Hospital of Fudan University, Shanghai 201102, P.R. China Correspondence to: Mr. Zhigao Chen, Department of Pharmacy, The People’s Hospital of Jiangyin, 163 Shoushan Road, Jiangyin, Jiangsu 214400, P.R. China, E-mail: chenzhigaojy@sina.com Mr. Dongdong Wang, Department of Pharmacy, Children’s Hospital of Fudan University, 399 Wanyuan Road, Minhang, Shanghai 201102, P.R. China, E-mail: 13852029591@163.com

Contributed equally

 02 2019 26 11 2018 43 2 709 716 28 08 2018 21 11 2018 Copyright: © Chen et al. 2019 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Astragaloside IV (AST) is the major active saponin in Astragalus membranaceus and, reportedly, has a variety of pharmacological activities. However, the potential of AST to ameliorate high glucose-mediated renal tubular epithelial-mesenchymal transition (EMT) remains undetermined. The aim of the present research was to explore the effect and mechanism of AST in EMT of renal tubular epithelial cells, as an underlying mechanism of renal fibrosis and a vital feature involved in diabetic nephropathy. The effect of AST on the EMT of renal tubular epithelial cells (HK-2) stimulated by high glucose was investigated and it was attempted to elucidate the potential underlying mechanism. The expression of E-cadherin and α-smooth muscle actin were determined by western blotting and immunofluorescence assays. The expression of the mammalian target of rapamycin complex 1 (mTORC1)/ ribosomal protein S6 kinase β-1 (p70S6K) signaling pathway and protein levels of four transcriptional factors (snail, slug, twist and zinc finger E-box-binding homeobox 1) were also determined by western blotting. Additionally, extracellular matrix components, including fibronectin (FN) and collagen type IV (Col IV) were detected by ELISA. The results suggested that the EMT of HK-2 cells and the mTORC1/p70S6K pathway were activated by high glucose. The expression of snail and twist in HK-2 cells was elevated by high glucose. Furthermore, extracellular matrix components, FN and Col IV, were increased in HK-2 cells cultured with high glucose. In turn, treatment with AST reduced EMT features in HK-2 cells, inhibited mTORC1/p70S6K pathway activation, downregulated expression of snail and twist, and reduced secretion of FN and Col IV. In summary, the findings suggested that AST ameliorates high glucose-mediated renal tubular EMT by blocking the mTORC1/p70S6K signaling pathway in HK-2 cells.

 Key words astragaloside IV renal tubular epithelial-mesenchymal transition mammalian target of rapamycin complex 1/ribosomal protein S6 kinase β-1 signaling Introduction

Diabetes mellitus (DM) is a serious illness associated with an increased risk of cardiovascular complications, including dyslipidemia, coronary artery disease, hypertension and myocardial infarction (1,2). In addition to cardiovascular injury, two other affected vital organs are the kidney [diabetic nephropathy (DN)] and eyes (3), with DN being one of the most common complications for patients with diabetic (4,5). The pathogenesis of DN involves mesangial expansion, basement membrane thickening, glomerular hypertrophy and renal fibrosis (6-8), among which progressive renal fibrosis is the important pathological characteristic of DN (9). The epithelial-mesenchymal transition (EMT) of renal tubular epithelial cells is one of the underlying mechanisms of renal fibrosis and encompasses a range of events whereby epithelial cells no longer exhibit certain epithelial traits, such as E-cadherin expression, and instead acquire typical characteristics of mesenchymal cells, such as α-smooth muscle actin (α-SMA) expression (10). A number of studies have reported that the process is connected to the production of interstitial myofibro-blasts during nephropathy (11-13). Constant downregulation of E-cadherin is reported to occur via transcriptional repression, mediated by transcription factors including snail, slug, twist and zinc finger E-box-binding homeobox 1 (ZEB-1) (14-16), which control E-cadherin transcription by cross interaction with the E-box binding sites in the E-cadherin promoter (17,18). However, the cellular molecular mechanisms underlying EMT are not completely understood (19). Therefore, it is vital to clarify the pathogenic mechanisms of EMT to formulate appropriate interventions.

Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that regulates a series of growth-associated cellular processes. mTOR includes two complexes termed mTOR complex 1 (mTORC1) and complex 2 (mTORC2) (20). However, only mTORC1 is sensitive to rapamycin inhibition, and controls cell proliferation and growth via the phosphorylation of certain downstream targets, such as ribosomal protein S6 kinase β-1 (p70S6K) (20). Aberrant activation of the mTORC1/p70S6K pathway has been reported to be involved in the pathogenesis of DN (21). Furthermore, mTORC1/p70S6K signaling may mediate renal tubular EMT during DN (19).

Astragaloside IV (AST) is a small molecular saponin that is one of the main active ingredients extracted from Astragalus membranaceus (22,23). Growing evidence has confirmed that AST has a wide spectrum of pharmacological effects (24-28). However, to the best of our knowledge, the effect of AST on the EMT of renal tubular cells during DN has not yet been reported. Therefore, the present study was performed to investigate whether AST has an effect on EMT in renal tubular cells and to clarify the potential mechanisms involved.

 Materials and methods Cell culture and intervention

HK-2, the human proximal tubular epithelial cell line, was obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 5.56 mmol/l D-glucose [normal glucose (NG)]. For induction of EMT, the HK-2 cells (at ~60% confluence) were cultivated with high glucose (HG) medium including 60 mmol/l D-glucose for 72 h (19). Mannitol medium including 5.56 mmol/l glucose and 54.44 mmol/l mannitol, was used as an osmotic control (MA). AST, purchased from Shanghai YuanYe Biotechnology Co., Ltd. (Shanghai, China), was added when the cell culture medium was changed from NG to HG medium at a concentration of 50 µg/ml [AST low (ASTL)], 100 µg/ml [AST medium (ASTM)] or 200 µg/ml [AST high (ASTH)]. For the rapamycin administration group (Rap), rapamycin (Cell Signaling Technology, Inc., Danvers, MA, USA) was added at a concentration of 20 nmol/l (19).

 Western blot analysis

Protein was isolated from HK-2 cells using lysis buffer including 1% NP-40, 1 mmol/l Na3VO4, 1 mmol/l phenylmethylsulfonyl fluoride, 1 mmol/l EDTA, 20 mmol/l NaF, 50 mmol/l Tris (pH 7.6), and 150 mmol/l NaCl. The concentration of proteins was measured with a bicinchoninic acid protein assay kit (Beyotime Institute of Biotechnology, Haimen, China) following the manufacturer’s protocol. For immunoblotting, equivalent quantities of protein (80 µg) from the different groups were separated by SDS-PAGE on 8% gels and transferred onto polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA), which were blocked in TBS-Tween containing 3% bovine serum albumin (BSA) at room temperature for 1 h, and then incubated with primary antibodies at 4°C overnight. The primary antibodies against mTOR (cat. no. 2983T; 1:1,000), phospho-mTOR (Ser2448; cat. no. 5536T; 1:1,000), p70S6K (cat. no. 2708T; 1:1,000), phospho-p70S6K (Thr389; cat. no. 9234T; 1:1,000), snail (cat. no. 3879T; 1:1,000), slug (cat. no. 9585T; 1:1,000), twist (cat. no. 46702S; 1:1,000), ZEB-1 (cat. no. A1500; 1:1,000) and E-cadherin (cat. no. 3195T; 1:1,000) were purchased from Cell Signaling Technology, Inc., and against α-SMA (cat. no. ab32575; 1:1,000) and GAPDH (cat. no. ab181602; 1:1,000) from Abcam (Cambridge, UK). Secondary antibody (cat. no. C40721-02; 1:1,000) was obtained from LI-COR Biosciences, (Lincoln, NE, USA) and incubation was at 4°C overnight. Quantification was performed by measuring the signal intensity of the protein bands with ImageJ software v1.46 (National Institutes of Health, Bethesda, MD, USA).

 Immunofluorescence

HK-2 cells (3×104/ml) were seeded into 12-well plates containing glass coverslips. Following treatment, they were washed three times with cold PBS and then fixed with 100% cold methanol for 20 min at -20°C. Following three more washes with PBS, the HK-2 cells were blocked in 5% BSA at room temperature for 1 h, and then labeled with E-cadherin (1:200; cat. no. 3195T; Cell Signaling Technology, Inc.) and α-SMA (1:500; cat. no. ab32575; Abcam) antibodies at room temperature for 2 h. The slips were then incubated with DyLight 594 donkey anti-rabbit IgG (1:200; cat. no. E032421-01; EarthOx Life Sciences, Millbrae, CA, USA) for 1 h at room temperature. Subsequently, the nuclei were counter-stained with DAPI for 2 min, and then the cells were washed with PBS three times prior to mounting with fluorescence mounting medium. Images were captured with an Olympus BX43F fluorescence microscope (Olympus Corporation, Tokyo, Japan).

 ELISA

The protein levels of fibronectin (FN) and collagen type IV (Col IV) were measured via enzyme-linked immunosorbent assays (cat. nos. 30357H and 30588H; Shanghai Boyun Biotech Co., Ltd., Shanghai, China;) according to the manufacturer’s instructions.

 Statistical analysis

Data are expressed as means ± standard error. Statistical analyses were performed using one-way analysis of variance for multiple data comparisons, followed by the Neuman-Keuls test. P<0.05 was considered to indicate a statistically significant difference.

 Results Effects of AST on E-cadherin expression

As demonstrated in Fig. 1A and B, the HG group exhibited significantly lower E-cadherin expression compared with the NG group (P<0.01). Additionally, the expression level of E-cadherin in the MA group did not differ significantly to that in the NG group, indicating that there were no obvious effects generated by the osmotic pressure. Rapamycin administration increased the expression of E-cadherin compared with HG treatment (P<0.01). Notably, the ASTM- and ASTH-treated groups also exhibited markedly higher E-cadherin expression compared with the HG group (P<0.05 and P<0.01, respectively). These results revealed E-cadherin expression was decreased in HK-2 cells induced by high glucose, detected by western blotting and immunofluorescence, while ASTM- and ASTH treatment could increase E-cadherin expression compared with HG (Fig. 1C).

 Effects of AST on α-SMA expression

Expression of α-SMA was upregulated in the HG group compared with the NG group (P<0.01; Fig. 2A and B). Additionally, there was no significant difference between the NG and MA groups, indicating no obvious effects generated by the osmotic pressure. In the rapamycin group, the mTOR inhibitor downregulated α-SMA expression compared with HG treatment alone (P<0.01), and administration of AST could also significantly decrease the expression of α-SMA compared with HG alone (P<0.01). The results were validated by immunofluorescence (Fig. 2C).

 Effects of AST on mTORC1/p70S6K signaling

As demonstrated in Fig. 3A and B, the HG group exhibited markedly higher levels of phosphorylated mTOR compared with the NG group (P<0.01). Additionally, the phosphorylation of p70S6K, a main downstream target of mTOR, was also significantly increased in the HG group compared with in the NG group (P<0.01; Fig. 3C and D). These results revealed that HG activated mTORC1/p70S6K signaling. Furthermore, rapamycin reversed the abnormal activation induced by HG (P<0.01). There was no significant difference between the NG and MA groups, indicating no obvious effects generated by the osmotic pressure alone. Notably, the AST downregulated the phosphorylation of mTOR and its main downstream target, p70S6K, indicating that AST inhibits mTORC1/p70S6K signaling.

 Effects of AST on transcription factors (snail, slug, twist and ZEB-1)

E-cadherin is a marker protein of epithelial layers and its expression is downregulated when EMT occurs (14-16,19). The zinc finger transcription factors (snail, slug, twist and ZEB-1) suppress E-cadherin expression (14-16,19). To verify whether these transcription factors have a role in EMT of HK-2 cells induced by high glucose, the protein expression of snail, slug, twist and ZEB-1 was determined. The expression of snail and twist was significantly enhanced in the HG group compared with in the NG group (P<0.01), while slug and ZEB-1 expression exhibited no significant changes (Fig. 4). Meanwhile, rapamycin treatment could decrease the expression of snail and twist when compared with HG treatment (P<0.01). Interestingly, the AST administrations could also down-regulate the protein levels of snail and twist (P<0.05, P<0.01). In addition, there was no significant difference between the NG and MA groups, indicating no obvious effects generated by the osmotic pressure alone.

 Effects of AST on FN and Col IV

The major extracellular matrix (ECM) proteins FN and Col IV are regarded as markers of fibrogenesis and can cause renal fibrosis when accumulated in DN. As evident in Fig. 5, the protein levels of FN and Col IV were significantly increased in the HG group compared with in the NG group (P<0.01); and no significant differences were observed between the MA and NG groups, indicating no marked effects generated by the osmotic pressure alone. In turn, treatment with rapamycin or AST downregulated the elevated FN and Col IV levels compared with HG treatment (P<0.01).

 Discussion

The incidence of DM has been increasing worldwide and as a secondary complication, DN is one of the most significant causes of end-stage renal disease (29,30). In China (31) and the United States (32), ~16 and 26% of patients with DN develop end-stage renal disease, respectively; thus, effective and safe treatment strategies to delay the progression of DN are urgently required in the clinic (21). However, little progress has been made in the treatment of patients with DN (33). Although certain novel drugs, including dipeptidyl peptidase 4 inhibitors (34-36), sodium glucose cotransporter 2 inhibitors (37,38) and glucagon-like peptide 1 agonists (39), can help patients presenting with early-stage DN by tightly controlling blood glucose level, it remains largely unknown whether these drugs can ameliorate EMT of renal tubular cells, which also occurs in DN.

Astragalus membranaceus, a traditional Chinese herbal medicine, is widely used as a remedy in the treatment of a variety of clinical diseases, including seasonal allergic rhinitis (40), ischemic heart disease (41), leucopenia (42) and DN (43). AST is one of the main active ingredients of Astragalus membranaceus, the potential pharmaceutical properties of which may include anti-inflammatory (25), anti-oxidative injury (44), anti-cancer (28), anti-hepatitis (27), anti-chronic heart failure (26) and anti-diabetes effects (24,45). The current study aimed to determine whether AST altered EMT in renal tubular cells and to verify the potential mechanisms involved. To the best of our knowledge, the current study is the first to explore the effect and mechanism of AST on the EMT of renal tubular epithelial cells and whether the mTORC1/p70S6K signaling pathway in involved in this effect.

EMT is a physiological process required for wound healing, tissue remodeling and embryogenesis (19); however, EMT is also implicated in pathological processes of various diseases (13,46). For example, during DN, renal tubular epithelial cells undergo a trans-differentiation process and become myofibroblasts, which are the primary source of ECM in renal cells. Major ECM proteins, including FN and Col IV, are often regarded as markers of fibrogenesis (47-49), and their accumulation in patients with DN can lead to renal fibrosis (11,50).

In the present study, the detection of EMT marker proteins demonstrated that high glucose significantly downregulated E-cadherin expression and upregulated the generation of α-SMA. Furthermore, levels of FN and Col IV were increased by high glucose. In turn, treatment with AST could ameliorate the changes stimulated by high glucose. Previous studies have indicated that the mTORC1/p70S6K pathway has an important role in DN, with blockade of this pathway reported to slow DN development (19,21).

It was previously reported that quercetin effectively ameliorated the high glucose-induced EMT of HK-2 and NRK-52E cells and inhibited the activation of mTORC1/p70S6K (19). In vivo, diabetic rats exhibited a significant decline in renal function and severe renal fibrosis at 14 weeks after STZ injection, and mTORC1/p70S6K was activated in the renal cortex of the diabetic rats. Treatment with quercetin alleviated the decline in renal function, and the progression of renal fibrosis and inhibited mTORC1/p70S6K activation in the diabetic renal cortex (19). A HK-2 cell model was validated in the previous study, and based on this, HK-2 cells treated with high glucose was selected as the cell model to verify the effects of AST on EMT in the present study. The results of the current study confirmed previous findings, revealing that the phosphorylation of mTOR and its downstream target, p70S6K, was markedly increased in HK-2 cells induced by high glucose. Treatment with rapamycin inhibited the activation of the mTORC1/p70S6K pathway. Additionally, the association of mTORC1/p70S6K signaling with the EMT of renal tubular epithelial cells was confirmed. Notably, a study by Lu et al (19) indicated that the mTORC1/p70S6K pathway is also involved in the regulation of transcription factor expression, including snail and twist. In the present study, inhibiting mTORC1/p70S6K signaling via rapamycin downregulated the increased protein expression of snail and twist induced by high glucose. These results indicated that activation of mTORC1/p70S6K signaling promoted the progression of EMT by regulating snail and twist expression. Furthermore, AST administration inhibited the mTORC1/p70S6K pathway and reduced the expression of snail and twist; the potential mechanism is illustrated in Fig. 6. However, not studying more markers was a limitation of the present study. The findings of the present study require further validation in the future.

In conclusion, to the best of our knowledge, the present study is the first research to determine the effects of AST on EMT in HK-2 cells via the mTORC1/p70S6K signaling pathway. The present findings provided confirmation that AST reduces EMT in renal tubular cells stimulated by high glucose via mTORC1/p70S6K signaling, and subsequent downregulation of the expression of the transcription factors snail and twist in HK-2 cells. The conclusions will be validated using in vivo models in future studies.

 Funding

The present study was supported by the Young Medical Talents of Wuxi (grant no. QNRC020), Young Project of Wuxi Health and Family Planning Research (grant no. Q201706), and Wuxi Science and Technology Development Guidance Plan (Medical and Health Care; grant no. CSZON1744).

 Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

 Authors’ contributions

DW and ZC conceived and designed the study. DW, XC, YY and CL performed the experiments. DW and XC wrote the paper. YY and CL critically reviewed and edited the manuscript. All authors read and approved the final manuscript.

 Ethics approval and consent to participate

Not applicable.

 Patient consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 Acknowledgments

Not applicable.

 References DixitPGhaskadbiSMohanHDevasagayamTPAntioxidant properties of germinated fenugreek seedsPhytother Res19977983200510.1002/ptr.176916317656 RobertsKTThe potential of fenugreek (Trigonella foenum-graecum) as a functional food and nutraceutical and its effects on glycemia and lipidemiaJ Med Food1414851489201110.1089/jmf.2011.000221861724 KashiharaNHarunaYKondetiVKKanwarYSOxidative stress in diabetic nephropathyCurr Med Chem1742564269201010.2174/092986710793348581209398143708695 CollinsAJFoleyRNHerzogCChaversBGilbertsonDIshaniAKasiskeBLiuJMauLWMcBeanMUS Renal Data System 2010 Annual Data ReportAm J Kidney Dis57Suppl 1A8e1e526201110.1053/j.ajkd.2010.10.007 ReutensATAtkinsRCEpidemiology of diabetic nephropathyContrib Nephrol17017201110.1159/00032493421659752 BrosiusFCKhouryCCBullerCLChenSAbnormalities in signaling pathways in diabetic nephropathyExpert Rev Endocrinol Metab55164201010.1586/eem.09.70202248022834210 SteffesMWOsterbyRChaversBMauerSMMesangial expansion as a central mechanism for loss of kidney function in diabetic patientsDiabetes3810771081198910.2337/diab.38.9.10772670639 ZiyadehFNThe extracellular matrix in diabetic nephropathyAm J Kidney Dis22736744199310.1016/S0272-6386(12)80440-98238022 ValcourtUKowanetzMNiimiHHeldinCHMoustakasATGF-beta and the Smad signaling pathway support tran-scriptomic reprogramming during epithelial-mesenchymal cell transitionMol Biol Cell1619872002200510.1091/mbc.e04-08-0658156894961073677 BadidCDesmouliereABabiciDHadj-AissaAMcGregorBLefrancoisNTouraineJLLavilleMInterstitial expression of alpha-SMA: An early marker of chronic renal allograft dysfunctionNephrol Dial Transplant1719931998200210.1093/ndt/17.11.199312401859 HillsCESquiresPEThe role of TGF-β and epithelial-to mesenchymal transition in diabetic nephropathyCytokine Growth Factor Rev22131139201121757394 LiuYNew insights into epithelial-mesenchymal transition in kidney fibrosisJ Am Soc Nephrol21212222201010.1681/ASN.2008121226 ThieryJPAcloqueHHuangRYNietoMAEpithelial-mesenchymal transitions in development and diseaseCell139871890200910.1016/j.cell.2009.11.00719945376 NietoMAThe snail superfamily of zinc-finger transcription factorsNat Rev Mol Cell Biol3155166200210.1038/nrm75711994736 PeinadoHOlmedaDCanoASnail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotypeNat Rev Cancer7415428200710.1038/nrc213117508028 ThieryJPSleemanJPComplex networks orchestrate epithelial-mesenchymal transitionsNat Rev Mol Cell Biol7131142200610.1038/nrm183516493418 CanoAPérez-MorenoMARodrigoILocascioABlancoMJdel BarrioMGPortilloFNietoMAThe transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expressionNat Cell Biol27683200010.1038/3500002510655586 HajraKMChenDYFearonERThe SLUG zinc-finger protein represses E-cadherin in breast cancerCancer Res6216131618200211912130 LuQJiXJZhouYXYaoXQLiuYQZhangFYinXXQuercetin inhibits the mTORC1/p70S6K signaling-mediated renal tubular epithelial-mesenchymal transition and renal fibrosis in diabetic nephropathyPharmacol Res99237247201510.1016/j.phrs.2015.06.00626151815 MaXMBlenisJMolecular mechanisms of mTOR-mediated translational controlNat Rev Mol Cell Biol10307318200910.1038/nrm267219339977 WuWHuWHanWBLiuYLTuYYangHMFangQJZhouMYWanZYTangRMInhibition of Akt/mTOR/p70S6K Signaling Activity With Huangkui Capsule Alleviates the Early Glomerular Pathological Changes in Diabetic NephropathyFront Pharmacol9443201810.3389/fphar.2018.00443298813495976825 LiMQuYZZhaoZWWuSXLiuYYWeiXYGaoLGaoGDAstragaloside IV protects against focal cerebral ischemia/reperfusion injury correlating to suppression of neutrophils adhesion-related moleculesNeurochem Int60458465201210.1016/j.neuint.2012.01.02622342823 LuoYQinZHongZZhangXDingDFuJHZhangWDChenJAstragaloside IV protects against ischemic brain injury in a murine model of transient focal ischemiaNeurosci Lett363218223200410.1016/j.neulet.2004.03.03615182947 DuQZhangSLiAMohammadISLiuBLiYAstragaloside IV: Astragaloside IV Inhibits Adipose Lipolysis and Reduces Hepatic Glucose Production via Akt Dependent PDE3B Expression in HFD-Fed MiceFront Physiol915201810.3389/fphys.2018.00015 LiCYangFLiuFLiDYangTNRF2/HO-1 activation via ERK pathway involved in the anti-neuroinflammatory effect of Astragaloside IV in LPS induced microglial cellsNeurosci Lett666104110201810.1016/j.neulet.2017.12.039 TangBZhangJGTanHYWeiXQAstragaloside IV inhibits ventricular remodeling and improves fatty acid utili-zation in rats with chronic heart failureBiosci Rep3838201810.1042/BSR20171036 WangSLiJHuangHGaoWZhuangCLiBZhouPKongDAnti-hepatitis B virus activities of astragaloside IV isolated from radix AstragaliBiol Pharm Bull32132135200910.1248/bpb.32.13219122295 ZhuJWenKAstragaloside IV inhibits TGF-β1-induced epithelial-mesenchymal transition through inhibition of the PI3K/Akt/NF-κB pathway in gastric cancer cellsPhytother Res3212891296201810.1002/ptr.605729480652 BrownleeMThe pathobiology of diabetic complications: A unifying mechanismDiabetes5416151625200510.2337/diabetes.54.6.161515919781 ShawJESicreeRAZimmetPZGlobal estimates of the prevalence of diabetes for 2010–2030Diabetes Res Clin Pract87414201010.1016/j.diabres.2009.10.007 LiuZHNephrology in chinaNat Rev Nephrol9523528201310.1038/nrneph.2013.14623877587 AfkarianMZelnickLRHallYNHeagertyPJTuttleKWeissNSde BoerIHClinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988–2014JAMA316602610201610.1001/jama.2016.10924275329155444809 de BoerIHA new chapter for diabetic kidney diseaseN Engl J Med377885887201710.1056/NEJMe170894928854097 PennoGGarofoloMDel PratoSDipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injuryNutr Metab Cardiovasc Dis26361373201610.1016/j.numecd.2016.01.00127105869 WangDZhangGChenXWeiTLiuCChenCGongYWeiQSitagliptin ameliorates diabetic nephropathy by blocking TGF-β1/Smad signaling pathwayInt J Mol Med41278427922018294843815846674 ZhangGYWangDDCaoZWeiTLiuCXWeiQLSitagliptin ameliorates high glucose-induced cell proliferation and expression of the extracellular matrix in glomerular mesangial cellsExp Ther Med1438623867201710.3892/etm.2017.5002290429935639317 WannerCInzucchiSELachinJMFitchettDvonEynatten MMattheusMJohansenOEWoerleHJBroedlUCZinmanBEmpagliflozin and progression of kidney disease in type 2 diabetesN Engl J Med375323334201610.1056/NEJMoa151592027299675 ZinmanBWannerCLachinJMFitchettDBluhmkiEHantelSMattheusMDevinsTJohansenOEWoerleHJEmpagliflozin, cardiovascular outcomes, and mortality in type 2 diabetesN Engl J Med37321172128201510.1056/NEJMoa150472026378978 MuskietMHATonneijckLSmitsMMvan BaarMJBKramerMHHHoornEJJolesJAvan RaalteDHGLP-1 and the kidney: From physiology to pharmacology and outcomes in diabetesNat Rev Nephrol13605628201710.1038/nrneph.2017.12328869249 MatkovicZZivkovicVKoricaMPlavecDPecanicSTudoricNEfficacy and safety of Astragalus membranaceus in the treatment of patients with seasonal allergic rhinitisPhytother Res241751812010 LiSQYuanRXGaoHClinical observation on the treatment of ischemic heart disease with Astragalus membranaceusZhongguo Zhong Xi Yi Jie He Za Zhi1577801995In Chinese7787395 ZhangCZhuCLingYZhouXDongCLuoJLiuYThe clinical value of Huangqi injection in the treatment of leucopenia: A meta-analysis of clinical controlled trialsPLoS One8e83123201310.1371/journal.pone.0083123243494443861487 LiMWangWXueJGuYLinSMeta-analysis of the clinical value of Astragalus membranaceus in diabetic nephropathyJ Ethnopharmacol133412419201110.1016/j.jep.2010.10.012 QiaoYFanCLTangMKAstragaloside IV protects rat retinal capillary endothelial cells against high glucose-induced oxidative injuryDrug Des Devel Ther1135673577201710.2147/DDDT.S152489292636525732560 ChenXWangDDWeiTHeSMZhangGYWeiQLEffects of astragalosides from Radix Astragali on high glucose-induced proliferation and extracellular matrix accumulation in glomerular mesangial cellsExp Ther Med1125612566201610.3892/etm.2016.3194273136764888024 NietoMAEpithelial-Mesenchymal Transitions in development and disease: Old views and new perspectivesInt J Dev Biol5315411547200910.1387/ijdb.072410mn19247945 GonzalezJKleinJChauhanSDNeauECaliseDNevoitCChaayaRMiraveteMDelageCBascandsJLDelayed treatment with plasminogen activator inhibitor-1 decoys reduces tubulointerstitial fibrosisExp Biol Med (Maywood)23415111518200910.3181/0903-RM-105 WangJYYinXXWuYMTangDQGaoYYWanMRHouXYZhangBGinkgo biloba extract suppresses hypertrophy and extracellular matrix accumulation in rat mesangial cellsActa Pharmacol Sin2712221230200610.1111/j.1745-7254.2006.00360.x16923344 XuWShaoXTianLGuLZhangMWangQWuBWangLYaoJXuXAstragaloside IV ameliorates renal fibrosis via the inhibition of mitogen-activated protein kinases and antiapoptosis in vivo and in vitroJ Pharmacol Exp Ther350552562201410.1124/jpet.114.21420524951279 LiYKangYSDaiCKissLPWenXLiuYEpithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuriaAm J Pathol172299308200810.2353/ajpath.2008.070057182021932312375

Effects of AST on E-cadherin expression in HK-2 cells. (A) Western blot analysis of E-cadherin. (B) Densitometry analysis of E-cadherin. (C) Expression of E-cadherin via immunofluorescence. Data are expressed as the mean ± standard error. n=3. Scale bar, 20 µm. **P<0.01 vs. NG; #P<0.05 vs. HG group; ##P<0.01 vs. HG group. AST, astragaloside IV; NG, normal glucose 5.56 mmol/l; MA, normal glucose 5.56 mmol/l + mannitol 54.44 mmol/l; HG, high glucose 60 mmol/l; Rap, high glucose + 20 nmol/l rapamycin; ASTL, high glucose + 50 µg/ml AST; ASTM, high glucose + 100 µg/ml AST; ASTH, high glucose + 200 µg/ml AST.

Effects of AST on α-SMA expression in HK-2 cells. (A) Western blotting bands of α-SMA. (B) Densitometry analysis of α-SMA. (C) Expression of α-SMA via immunofluorescence. Data are expressed as the mean ± standard error. n=3. Scale bar, 20 µm.**P<0.01 vs. NG; ##P<0.01 vs. HG group. AST, astragaloside IV; NG, normal glucose 5.56 mmol/l; MA, normal glucose 5.56 mmol/l + mannitol 54.44 mmol/l; HG, high glucose 60 mmol/l; Rap, high glucose + 20 nmol/l rapamycin; ASTL, high glucose + 50 µg/ml AST; ASTM, high glucose + 100 µg/ml AST; ASTH, high glucose + 200 µg/ml AST; α-SMA, α-smooth muscle actin.

Effects of AST on mTORC1/p70S6K signaling in HK-2 cells. (A) Western blot analysis of p-mTOR. (B) Densitometry analysis of p-mTOR. (C) Western blot analysis of p-p70S6K. (D) Densitometry analysis of p-p70S6K. Data are expressed as mean ± standard error. n=3. **P<0.01 vs. NG group; #P<0.05 vs. HG group; ##P<0.01 vs. HG group. AST, astragaloside IV; NG, normal glucose 5.56 mmol/l; MA, normal glucose 5.56 mmol/l + mannitol 54.44 mmol/l; HG, high glucose 60 mmol/l; Rap, high glucose + 20 nmol/l rapamycin; ASTL, high glucose + 50 µg/ml AST; ASTM, high glucose + 100 µg/ml AST; ASTH, high glucose + 200 µg/ml AST; p- phospho-; mTOR, mammalian target of rapamycin; p70S6K, ribosomal protein S6 kinase β-1.

Effects of AST on transcriptional factors, snail, slug, twist and ZEB-1. (A) Western blot analysis of snail, slug, twist and ZEB-1. Relative abundance of (B) snail, (C) slug, (D) twist and (E) ZEB-1. Data are expressed as mean ± standard error. n=3. **P<0.01 vs. NG group; #P<0.05 vs. HG group; ##P<0.01 vs. HG group. AST, astragaloside IV; NG, normal glucose 5.56 mmol/l; MA, normal glucose 5.56 mmol/l + mannitol 54.44 mmol/l; HG, high glucose 60 mmol/l; Rap, high glucose + 20 nmol/l rapamycin; ASTL, high glucose + 50 µg/ml AST; ASTM, high glucose + 100 µg/ml AST; ASTH, high glucose + 200 µg/ml AST; ZEB-1, zinc finger E-box-binding homeobox 1.

Effects of AST on FN and IV Col. (A) Relative abundance of FN. (B) Relative abundance of IV Col. Data are expressed as the mean ± standard error. n=3. **P<0.01 vs. NG group; ##P<0.01 vs. HG group. FN, fibronectin; AST, astragaloside IV; NG, normal glucose 5.56 mmol/l; MA, normal glucose 5.56 mmol/l + mannitol 54.44 mmol/l; HG, high glucose 60 mmol/l; Rap, high glucose + 20 nmol/l rapamycin; ASTL, high glucose + 50 µg/ml AST; ASTM, high glucose + 100 µg/ml AST; ASTH, high glucose + 200 µg/ml AST; IV Col, collagen type IV.

Mechanism of AST ameliorates high glucose-mediated renal tubular epithelial-mesenchymal transition. AST, astragaloside IV; mTOR, mammalian target of rapamycin; p70S6K, ribosomal protein S6 kinase β-1; P, phospho-; α-SMA, α-smooth muscle actin; FN, fibronectin; IV Col, collagen type IV.